Thrombosis-Pipeline Review, H1 2015

Thrombosis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6511IDB
  • |
  • Pages: 271
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Thrombosis-Pipeline Review, H1 2015


Global Markets Direct's, 'Thrombosis-Pipeline Review, H1 2015', provides an overview of the Thrombosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Thrombosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Thrombosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Thrombosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Thrombosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 9

Global Markets Direct Report Coverage 9

Thrombosis Overview 10

Therapeutics Development 11

Pipeline Products for Thrombosis-Overview 11

Pipeline Products for Thrombosis-Comparative Analysis 12

Thrombosis-Therapeutics under Development by Companies 13

Thrombosis-Therapeutics under Investigation by Universities/Institutes 18

Thrombosis-Pipeline Products Glance 21

Late Stage Products 21

Clinical Stage Products 22

Early Stage Products 23

Thrombosis-Products under Development by Companies 24

Thrombosis-Products under Investigation by Universities/Institutes 30

Thrombosis-Companies Involved in Therapeutics Development 33

Archemix Corp. 33

Arena Pharmaceuticals, Inc. 34

Armetheon, Inc. 35

Arrowhead Research Corporation 36

Astellas Pharma Inc. 37

AstraZeneca Plc 38

Bayer AG 39

Bristol-Myers Squibb Company 40

Cardax Pharmaceuticals, Inc. 41

Cereno Scientific AB 42

China Biologic Products, Inc. 43

CSL Limited 44

Daewoong Pharmaceutical Co., Ltd. 45

Daiichi Sankyo Company, Limited 46

Eisai Co., Ltd. 47

F. Hoffmann-La Roche Ltd. 48

Gamma Therapeutics, Inc. 49

Generex Biotechnology Corporation 50

GlycoMimetics, Inc. 51

Green Cross Corporation 52

IMMD Inc. 53

Isis Pharmaceuticals, Inc. 54

Johnson & Johnson 55

Laboratorios Farmaceuticos Rovi, S.A. 56

LG Life Sciences, Ltd. 57

Lipicard Technologies Limited 58

Merrion Pharmaceuticals Plc 59

Nostrum Pharmaceuticals, LLC 60

Pfizer Inc. 61

PLx Pharma Inc. 62

Portola Pharmaceuticals, Inc. 63

Prothix BV 64

Sagene Pharmaceuticals, Inc. 65

Sanofi 66

SciFluor Life Sciences, LLC 67

Tobira Therapeutics, Inc. 68

Zedira GmbH 69

Thrombosis-Therapeutics Assessment 70

Assessment by Monotherapy Products 70

Assessment by Combination Products 71

Assessment by Target 72

Assessment by Mechanism of Action 76

Assessment by Route of Administration 80

Assessment by Molecule Type 82

Drug Profiles 84

AB-012-Drug Profile 84

antithrombin III (human)-Drug Profile 86

ANV-6L15-Drug Profile 87

apixaban-Drug Profile 88

ARC-15105-Drug Profile 90

ARCF-12-Drug Profile 91

AS-1468240-Drug Profile 92

ASP-1645-Drug Profile 93

ASP-6537-Drug Profile 94

aspirin-Drug Profile 95

BAY-1213790-Drug Profile 97

betrixaban-Drug Profile 98

BMS-262084-Drug Profile 100

BMS-593214-Drug Profile 101

BMS-816106-Drug Profile 102

BMS-884775-Drug Profile 103

BMS-986120-Drug Profile 104

BMS-986141-Drug Profile 105

C-3-Drug Profile 106

CDX-085-Drug Profile 107

CLB-100-Drug Profile 109

CSL-312-Drug Profile 110

DD-2-Drug Profile 111

Drug to Activate Endothelial Protein C Receptor for Inflammation and Thrombosis-Drug Profile 112

Drugs for Thrombosis-Drug Profile 113

DWJ-1261-Drug Profile 114

DWJ-1355-Drug Profile 115

E-5539-Drug Profile 116

edoxaban tosylate-Drug Profile 117

enoxaparin biosimilar-Drug Profile 119

enoxaparin sodium-Drug Profile 120

ER-410660-Drug Profile 121

fondaparinux sodium-Drug Profile 122

Gammarin-Drug Profile 123

GCC-2107-Drug Profile 124

GMI-1271-Drug Profile 125

IMD-4852-Drug Profile 126

Ir-CPI-Drug Profile 127

ISIS-FVIIRx-Drug Profile 128

ISIS-FXIRx-Drug Profile 129

JNJ-375-Drug Profile 130

LC-231306-Drug Profile 131

LT-5121-Drug Profile 132

LT-5122-Drug Profile 133

LT5521-Drug Profile 134

Lysimab-Drug Profile 135

Monoclonal Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke-Drug Profile 136

NPB-06-Drug Profile 137

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction-Drug Profile 138

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism-Drug Profile 139

Peptides for Immunology and Cardiovascular Disorders-Drug Profile 140

PF-00190434-Drug Profile 141

PRO-01-Drug Profile 142

Protein for Thromboembolism-Drug Profile 143

PRT-060318-Drug Profile 145

PZ-128-Drug Profile 146

Recombinant Protein for Thrombosis and Non-Small Cell Lung Cancer-Drug Profile 147

Recombinant Protein for Thrombosis and Stroke-Drug Profile 148

Recombinant Protein Slit2 to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis-Drug Profile 149

Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis-Drug Profile 150

REG-2-Drug Profile 151

rGPG-290-Drug Profile 153

rivaroxaban-Drug Profile 154

RNAi Oligonucleotide for DVT-Drug Profile 159

S-002333-Drug Profile 160

S-007867-Drug Profile 161

SAR-216471-Drug Profile 162

selegiline + Antiplatelet Drugs-Drug Profile 163

semuloparin-Drug Profile 164

Small Molecule for Thrombosis-Drug Profile 165

Small Molecule for Thrombosis-Drug Profile 166

Small Molecule to Antagonize P2Y12 for Thrombosis-Drug Profile 167

Small Molecule to Antagonize PAR4 for Thromboembolic Disorders-Drug Profile 168

Small Molecule to Inhibit ASK1 for Thrombosis-Drug Profile 169

Small Molecule to Inhibit Factor XIa for Thrombosis-Drug Profile 170

Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis-Drug Profile 171

Small Molecule To inhibit PAR-1 for Atherothrombosis-Drug Profile 172

Small Molecules for Hematological Disorders and Cancer-Drug Profile 173

Small Molecules for Thrombosis-Drug Profile 174

Small Molecules for Thrombosis and Stroke-Drug Profile 175

Small Molecules to Inhibit Carboxypeptidase U for Thrombosis-Drug Profile 176

Small Molecules to Inhibit Factor XIII for Thrombosis-Drug Profile 177

Small Molecules to Inhibit HDAC for Thromboembolism-Drug Profile 178

Small Molecules to Inhibit P2Y12 Receptor for Thrombosis-Drug Profile 179

Small Molecules to Inhibit PDI for Thrombosis-Drug Profile 180

Small Molecules to Inhibit Thrombin for Thrombosis and Oncology-Drug Profile 181

Small Molecules to Inhibit TNF-a for Cardiovascular and CNS Disorders-Drug Profile 182

SMRX-11-Drug Profile 183

Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury-Drug Profile 184

Synthetic Peptides to Inhibit Glycoprotein VI for Thrombosis-Drug Profile 185

Tanshinone IIA-Drug Profile 186

TAP-ANV-Drug Profile 187

tecarfarin sodium-Drug Profile 188

temanogrel hydrochloride-Drug Profile 190

ticagrelor-Drug Profile 191

TM-5275-Drug Profile 195

TM-5509-Drug Profile 196

TRX-1-Drug Profile 197

TTS-01-Drug Profile 198

UM-8190-Drug Profile 199

YG-001-Drug Profile 200

Thrombosis-Recent Pipeline Updates 201

Thrombosis-Dormant Projects 237

Thrombosis-Discontinued Products 246

Thrombosis-Product Development Milestones 250

Featured News & Press Releases 250

Appendix 263

Methodology 263

Coverage 263

Secondary Research 263

Primary Research 263

Expert Panel Validation 263

Contact Us 263

Disclaimer 264

List of Tables

Number of Products under Development for Thrombosis, H1 2015 18

Number of Products under Development for Thrombosis-Comparative Analysis, H1 2015 19

Number of Products under Development by Companies, H1 2015 21

Number of Products under Development by Companies, H1 2015 (Contd..1) 22

Number of Products under Development by Companies, H1 2015 (Contd..2) 23

Number of Products under Development by Companies, H1 2015 (Contd..3) 24

Number of Products under Investigation by Universities/Institutes, H1 2015 25

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 27

Comparative Analysis by Late Stage Development, H1 2015 28

Comparative Analysis by Clinical Stage Development, H1 2015 29

Comparative Analysis by Early Stage Development, H1 2015 30

Products under Development by Companies, H1 2015 31

Products under Development by Companies, H1 2015 (Contd..1) 32

Products under Development by Companies, H1 2015 (Contd..2) 33

Products under Development by Companies, H1 2015 (Contd..3) 34

Products under Development by Companies, H1 2015 (Contd..4) 35

Products under Development by Companies, H1 2015 (Contd..5) 36

Products under Investigation by Universities/Institutes, H1 2015 37

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 38

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 39

Thrombosis-Pipeline by Archemix Corp., H1 2015 40

Thrombosis-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 41

Thrombosis-Pipeline by Armetheon, Inc., H1 2015 42

Thrombosis-Pipeline by Arrowhead Research Corporation, H1 2015 43

Thrombosis-Pipeline by Astellas Pharma Inc., H1 2015 44

Thrombosis-Pipeline by AstraZeneca Plc, H1 2015 45

Thrombosis-Pipeline by Bayer AG, H1 2015 46

Thrombosis-Pipeline by Bristol-Myers Squibb Company, H1 2015 47

Thrombosis-Pipeline by Cardax Pharmaceuticals, Inc., H1 2015 48

Thrombosis-Pipeline by Cereno Scientific AB, H1 2015 49

Thrombosis-Pipeline by China Biologic Products, Inc., H1 2015 50

Thrombosis-Pipeline by CSL Limited, H1 2015 51

Thrombosis-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 52

Thrombosis-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 53

Thrombosis-Pipeline by Eisai Co., Ltd., H1 2015 54

Thrombosis-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 55

Thrombosis-Pipeline by Gamma Therapeutics, Inc., H1 2015 56

Thrombosis-Pipeline by Generex Biotechnology Corporation, H1 2015 57

Thrombosis-Pipeline by GlycoMimetics, Inc., H1 2015 58

Thrombosis-Pipeline by Green Cross Corporation, H1 2015 59

Thrombosis-Pipeline by IMMD Inc., H1 2015 60

Thrombosis-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 61

Thrombosis-Pipeline by Johnson & Johnson, H1 2015 62

Thrombosis-Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H1 2015 63

Thrombosis-Pipeline by LG Life Sciences, Ltd., H1 2015 64

Thrombosis-Pipeline by Lipicard Technologies Limited, H1 2015 65

Thrombosis-Pipeline by Merrion Pharmaceuticals Plc, H1 2015 66

Thrombosis-Pipeline by Nostrum Pharmaceuticals, LLC, H1 2015 67

Thrombosis-Pipeline by Pfizer Inc., H1 2015 68

Thrombosis-Pipeline by PLx Pharma Inc., H1 2015 69

Thrombosis-Pipeline by Portola Pharmaceuticals, Inc., H1 2015 70

Thrombosis-Pipeline by Prothix BV, H1 2015 71

Thrombosis-Pipeline by Sagene Pharmaceuticals, Inc., H1 2015 72

Thrombosis-Pipeline by Sanofi, H1 2015 73

Thrombosis-Pipeline by SciFluor Life Sciences, LLC, H1 2015 74

Thrombosis-Pipeline by Tobira Therapeutics, Inc., H1 2015 75

Thrombosis-Pipeline by Zedira GmbH, H1 2015 76

Assessment by Monotherapy Products, H1 2015 77

Assessment by Combination Products, H1 2015 78

Number of Products by Stage and Target, H1 2015 80

Number of Products by Stage and Mechanism of Action, H1 2015 84

Number of Products by Stage and Route of Administration, H1 2015 88

Number of Products by Stage and Molecule Type, H1 2015 90

Thrombosis Therapeutics-Recent Pipeline Updates, H1 2015 208

Thrombosis-Dormant Projects, H1 2015 244

Thrombosis-Dormant Projects (Contd..1), H1 2015 245

Thrombosis-Dormant Projects (Contd..2), H1 2015 246

Thrombosis-Dormant Projects (Contd..3), H1 2015 247

Thrombosis-Dormant Projects (Contd..4), H1 2015 248

Thrombosis-Dormant Projects (Contd..5), H1 2015 249

Thrombosis-Dormant Projects (Contd..6), H1 2015 250

Thrombosis-Dormant Projects (Contd..7), H1 2015 251

Thrombosis-Dormant Projects (Contd..8), H1 2015 252

Thrombosis-Discontinued Products, H1 2015 253

Thrombosis-Discontinued Products (Contd..1), H1 2015 254

Thrombosis-Discontinued Products (Contd..2), H1 2015 255

Thrombosis-Discontinued Products (Contd..3), H1 2015 256

List of Figures

Number of Products under Development for Thrombosis, H1 2015 18

Number of Products under Development for Thrombosis-Comparative Analysis, H1 2015 19

Number of Products under Development by Companies, H1 2015 20

Number of Products under Investigation by Universities/Institutes, H1 2015 25

Comparative Analysis by Late Stage Development, H1 2015 28

Comparative Analysis by Clinical Stage Development, H1 2015 29

Comparative Analysis by Early Stage Products, H1 2015 30

Assessment by Monotherapy Products, H1 2015 77

Number of Products by Top 10 Targets, H1 2015 79

Number of Products by Stage and Top 10 Targets, H1 2015 79

Number of Products by Top 10 Mechanism of Actions, H1 2015 83

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 83

Number of Products by Top 10 Routes of Administration, H1 2015 87

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 87

Number of Products by Top 10 Molecule Types, H1 2015 89

Number of Products by Stage and Top 10 Molecule Types, H1 2015 89

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Archemix Corp.

Arena Pharmaceuticals, Inc.

Armetheon, Inc.

Arrowhead Research Corporation

Astellas Pharma Inc.

AstraZeneca Plc

Bayer AG

Bristol-Myers Squibb Company

Cardax Pharmaceuticals, Inc.

Cereno Scientific AB

China Biologic Products, Inc.

CSL Limited

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Eisai Co., Ltd.

F. Hoffmann-La Roche Ltd.

Gamma Therapeutics, Inc.

Generex Biotechnology Corporation

GlycoMimetics, Inc.

Green Cross Corporation


Isis Pharmaceuticals, Inc.

Johnson & Johnson

Laboratorios Farmaceuticos Rovi, S.A.

LG Life Sciences, Ltd.

Lipicard Technologies Limited

Merrion Pharmaceuticals Plc

Nostrum Pharmaceuticals, LLC

Pfizer Inc.

PLx Pharma Inc.

Portola Pharmaceuticals, Inc.

Prothix BV

Sagene Pharmaceuticals, Inc.


SciFluor Life Sciences, LLC

Tobira Therapeutics, Inc.

Zedira GmbH

Thrombosis Therapeutic Products under Development, Key Players in Thrombosis Therapeutics, Thrombosis Pipeline Overview, Thrombosis Pipeline, Thrombosis Pipeline Assessment

select a license

Single User License
USD 2000 INR 132420
Site License
USD 4000 INR 264840
Corporate User License
USD 6000 INR 397260



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]